GZMM polyclonal Antibody | BS60988

GZMM polyclonal Antibody | BS60988 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB

Application Range: WB: 1:500~1:1000

Background: The granzyme family of proteins belong to the larger peptidase S1 family. Granzyme A and granzyme B are serine proteases that facilitate apoptotic signaling in cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. Within the granules of activated CTLs, granzyme A and granzyme B are processed and converted to their active forms by the lysosomal cysteine protease cathepsin C. Once cleaved, these active proteases target distinct substrates for proteolysis, thereby mediating apoptosis through two different pathways. Granzyme H localizes to cytoplasmic granules of cytolytic T lymphocytes and is important for target cell lysis in cell-mediated immune responses. Granzyme K is a serine protease localizing to the granules of NK cells and cytotoxic T lymphocytes. Granzyme M (also designated NK cell granular protease, HU-Met-1 or met-1 serine protease) contains one peptidase S1 domain. Granzyme M is a Trypsin-fold serine protease that localizes to granules of large granular lymphocytes (NK cells) and cleaves peptide substrates after leucine, norleucine or methionine. This enzyme may play a role in target cell death induction by cytotoxic lymphocytes.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: GZMM polyclonal Antibody detects endogenous levels of GZMM protein.

Molecular Weight: ~ 28 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Granzyme M (EC:3.4.21.-) ; Met-1 serine protease; Hu-Met-1; Met-ase; Natural killer cell granular protease; GZMM; MET1

Immunogen: A synthetic peptide corresponding to residues in Human GZMM.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: